Collegium Pharmaceutical Inc

Collegium Pharmaceutical’s stock lags its 52‑week high; the biotech’s CNS, respiratory and skin drug pipeline and new Boston Legacy FC partnership offer growth potential amid cautious investor sentiment.

Collegium Pharmaceutical will participate in two investor conferences, the Mizuho Neuro & Ophthalmology Summit and the Jefferies Global Healthcare Conference, to discuss its strategic initiatives and growth prospects.